Content about Bortezomib

June 6, 2013
FDA approves Celgene drug for new cancer indication

The Food and Drug Administration has approved a drug made by Celgene for treating a type of cancer.

SUMMIT, N.J. — The Food and Drug Administration has approved a drug made by Celgene Corp. for treating a type of cancer.

Celgene announced Thursday the approval of Revlimid (lenalidomide) for treatment of patients with mantle cell lymphoma, also known as MCL, whose disease has relapsed or progressed after two prior therapies that have included bortezomib.

December 28, 2012
Watson confirms Velcade patent challenge

Watson Pharmaceuticals on Friday confirmed that Actavis, which was acquired by Watson in October, has filed an abbreviated new drug applications with the Food and Drug Administration seeking approval to market bortezomib, a generic version of Millennium Pharmaceuticals' Velcade.

PARSIPPANY, N.J. — Watson Pharmaceuticals on Friday confirmed that Actavis, which was acquired by Watson in October, has filed an abbreviated new drug applications with the U.S. Food and Drug Administration seeking approval to market bortezomib, a generic version of Millennium Pharmaceuticals' Velcade.

Bortezomib is a proteasome inhibitor for intravenous or subcutaneous administration, approved for treatment of patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior therapy.

July 23, 2012
FDA approves blood cancer drug

The Food and Drug Administration has approved a new drug for treating multiple myeloma, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating multiple myeloma, the agency said Friday.

January 24, 2012
FDA approves new administration method for Takeda cancer drug

The Food and Drug Administration has approved a new means of administering a cancer drug made by Takeda, the drug maker said.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved a new means of administering a cancer drug made by Takeda, the drug maker said.

The FDA approved injection under the skin of Velcade (bortezomib) for multiple myeloma and mantle-cell lymphoma, also known as subcutaneous injection.

Takeda said the approval was based on results of a phase-3 trial conducted on 222 patients who had not received the drug before that showed subcutaneous injection worked as well as intravenous injection.

November 2, 2011
FDA approves update to Takeda cancer drug label

The Food and Drug Administration has approved changes to the labeling of a cancer drug made by Takeda Pharmaceuticals, the drug maker said.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved changes to the labeling of a cancer drug made by Takeda Pharmaceuticals, the drug maker said.

Takeda and Millennium, the Japanese drug maker's cancer-drug subsidiary, announced Tuesday that the FDA approved a supplemental new drug application for the injectable multiple myeloma drug Velcade (bortezomib) that updates its label to include additional data from a clinical study showing that the drug extended patients' survival time.

March 21, 2010
Decision Resources projects more than 150% growth in multiple myeloma market

The market for drugs that treat a cancer of the bone marrow will more than...